- Previous Close
109.0000 - Open
-- - Bid 61.6000 x --
- Ask --
- Day's Range
-- - 52 Week Range
109.0000 - 109.0000 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
0 - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-0.00 - EPS (TTM)
-6.5000 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
www.ibtherapeutics.comRecent News: IBTBS.XC
View MorePerformance Overview: IBTBS.XC
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBTBS.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBTBS.XC
View MoreValuation Measures
Market Cap
740.93M
Enterprise Value
514.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.08%
Return on Equity (ttm)
-30.03%
Revenue (ttm)
10k
Net Income Avi to Common (ttm)
-99.19M
Diluted EPS (ttm)
-6.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
300.95M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-39.22M